AR092317A1 - Vectores virales para el tratamiento de distrofia retiniana - Google Patents
Vectores virales para el tratamiento de distrofia retinianaInfo
- Publication number
- AR092317A1 AR092317A1 ARP130101507A ARP130101507A AR092317A1 AR 092317 A1 AR092317 A1 AR 092317A1 AR P130101507 A ARP130101507 A AR P130101507A AR P130101507 A ARP130101507 A AR P130101507A AR 092317 A1 AR092317 A1 AR 092317A1
- Authority
- AR
- Argentina
- Prior art keywords
- viral vectors
- treatment
- retina
- retinian
- dystrophy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se relaciona con vectores virales capaces de entregar un gen heterólogo en la retina y en particular el de entregar genes RLBP1 en células RPE y células de Müller de la retina. La presente también se relaciona con ácidos nucleicos útiles en la producción de vectores virales, composiciones que comprenden los vectores virales y usos de las composiciones y vectores virales. La presente también se relaciona con métodos para entregar y/o expresar un gen heterólogo en la retina, mejorar la tasa de adaptación a la oscuridad en un sujeto y el tratamiento de la distrofia retiniana asociada con el RLBP1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642630P | 2012-05-04 | 2012-05-04 | |
US201361776167P | 2013-03-11 | 2013-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092317A1 true AR092317A1 (es) | 2015-04-15 |
Family
ID=48670626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101507A AR092317A1 (es) | 2012-05-04 | 2013-05-03 | Vectores virales para el tratamiento de distrofia retiniana |
Country Status (10)
Country | Link |
---|---|
US (5) | US9163259B2 (es) |
EP (2) | EP3326655A1 (es) |
JP (4) | JP6290185B2 (es) |
CN (2) | CN108753824B (es) |
AR (1) | AR092317A1 (es) |
CA (2) | CA2872447C (es) |
ES (1) | ES2947159T3 (es) |
TW (1) | TW201350581A (es) |
UY (1) | UY34780A (es) |
WO (1) | WO2013164793A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163259B2 (en) | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
EP3957735A1 (en) | 2014-03-05 | 2022-02-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11339437B2 (en) * | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
DK3116997T3 (da) | 2014-03-10 | 2019-08-19 | Editas Medicine Inc | Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10) |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
RU2716991C2 (ru) | 2014-11-05 | 2020-03-17 | Вояджер Терапьютикс, Инк. | Полинуклеотиды aadc для лечения болезни паркинсона |
JP6863891B2 (ja) | 2014-11-14 | 2021-04-21 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 調節性ポリヌクレオチド |
IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Preparations and methods for the treatment of amyotrophic lateral sclerosis |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
GB201516066D0 (en) * | 2015-09-10 | 2015-10-28 | Young & Co Llp D | Treatment of retinitis pigmentosa |
CA3006569A1 (en) | 2015-12-02 | 2017-06-08 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
EP3210632B1 (en) * | 2016-02-23 | 2022-09-28 | EyeServ GmbH | Gene therapy for the treatment of a retinal degeneration disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics Inc | composições e métodos de tratamento da doença de huntington |
IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
US11458211B2 (en) | 2016-07-12 | 2022-10-04 | The University Of Manchester | Gene therapy |
EP3494220A1 (en) | 2016-08-02 | 2019-06-12 | Editas Medicine, Inc. | Compositions and methods for treating cep290 associated disease |
CA3035522A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
CA3054711A1 (en) * | 2017-03-15 | 2018-09-20 | The University Of North Carolina At Chapel Hill | Polyploid adeno-associated virus vectors and methods of making and using the same |
US20200113972A1 (en) * | 2017-04-14 | 2020-04-16 | Rhode Island Hospital | Vegf gene therapy for tendon and ligament injuries |
AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Aavを送達するための組成物および方法 |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
EP3768327A4 (en) * | 2018-03-23 | 2022-04-13 | The Trustees of Columbia University in the City of New York | GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES |
MA52199A (fr) * | 2018-04-05 | 2021-02-17 | Nightstarx Ltd | Compositions et procédés de traitement de la dystrophie maculaire |
CA3112883A1 (en) * | 2018-10-25 | 2020-04-30 | Baxalta Incorporated | Aav triple-plasmid system |
US20220088222A1 (en) * | 2018-12-20 | 2022-03-24 | President And Fellows Of Harvard College | Compositions and methods for the treatment of degenerative ocular diseases |
CN113677801A (zh) * | 2019-02-25 | 2021-11-19 | 诺华股份有限公司 | 治疗bietti晶体营养不良的组合物和方法 |
WO2021050102A1 (en) * | 2019-09-09 | 2021-03-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb |
AU2020354670A1 (en) * | 2019-09-25 | 2022-04-21 | University Of Florida | Methods and compositions for the expression of constitutively active Rap1a from a VMD2 promoter |
WO2021064695A1 (en) | 2019-10-04 | 2021-04-08 | Novartis Ag | Methods for measuring cralbp activity |
EP4085143A4 (en) * | 2019-12-31 | 2024-02-28 | Swanbio Therapeutics Ltd | IMPROVED AAV-ABCD1 CONSTRUCTS AND USE FOR THE TREATMENT OR PREVENTION OF ADRENOLEUCODYSTROPHY (ALD) AND/OR ADRENOMYCESEUROPATHY (AMN) |
CA3169945A1 (en) * | 2020-04-07 | 2021-10-14 | Dongsheng Duan | Cpg-free itrs for aav gene therapy |
IL300785A (en) * | 2020-09-02 | 2023-04-01 | 4D Molecular Therapeutics Inc | RPGRORF 15 codon-optimized genes and their uses |
KR20240019755A (ko) * | 2021-03-19 | 2024-02-14 | 인터갈락틱 테라퓨틱스, 인크. | 치료제의 안구 전달 |
WO2022272056A2 (en) * | 2021-06-24 | 2022-12-29 | University Of Utah Research Foundation | Compositions and methods for treating pgm1 deficiency |
WO2023010133A2 (en) | 2021-07-30 | 2023-02-02 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
WO2023108130A2 (en) * | 2021-12-10 | 2023-06-15 | Aavantibio, Inc. | Compositions comprising kozak sequences selected for enhanced expression |
WO2024015881A2 (en) | 2022-07-12 | 2024-01-18 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US124068A (en) * | 1872-02-27 | Improvement in corn-husking and shelling machines | ||
AU678867B2 (en) | 1993-11-09 | 1997-06-12 | Medical College Of Ohio, The | Stable cell lines capable of expressing the adeno-associated virus replication gene |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US5945335A (en) | 1995-11-09 | 1999-08-31 | Avigen, Inc. | Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences |
JP2001506132A (ja) | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | Aavベクターの産生における使用のためのリコンビナーゼ活性化可能aavパッケージングカセット |
WO2000015822A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
EP1115880A2 (en) | 1998-09-22 | 2001-07-18 | University of Florida | Methods for large-scale production of recombinant aav vectors |
ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
US20040208847A1 (en) * | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
US7339042B2 (en) * | 2003-06-09 | 2008-03-04 | University Of Florida Research Foundation, Inc. | Gene delivery to tumors |
US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
WO2007078599A2 (en) * | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
US7740836B2 (en) | 2006-05-03 | 2010-06-22 | Fondazione Telethon | Methods and compositions for recovering or improving visual function |
US20100184838A1 (en) * | 2007-04-13 | 2010-07-22 | Tufts University | Compositions and methods for retinal transduction and photoreceptor specific transgene expression |
US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
WO2008150459A1 (en) | 2007-05-30 | 2008-12-11 | The Trustees Of The University Of Pennsylvania | A method for transducing cells with primary cilia |
EP2287323A1 (en) | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
WO2011034947A2 (en) | 2009-09-15 | 2011-03-24 | University Of Washington | Reagents and methods for modulating cone photoreceptor activity |
US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
-
2013
- 2013-04-30 US US13/873,558 patent/US9163259B2/en active Active
- 2013-05-02 JP JP2015509557A patent/JP6290185B2/ja active Active
- 2013-05-02 EP EP17204499.2A patent/EP3326655A1/en active Pending
- 2013-05-02 EP EP13730648.6A patent/EP2844302B1/en active Active
- 2013-05-02 CN CN201810593790.7A patent/CN108753824B/zh active Active
- 2013-05-02 ES ES13730648T patent/ES2947159T3/es active Active
- 2013-05-02 CA CA2872447A patent/CA2872447C/en active Active
- 2013-05-02 WO PCT/IB2013/053497 patent/WO2013164793A2/en active Application Filing
- 2013-05-02 CN CN201380035067.2A patent/CN104470545B/zh active Active
- 2013-05-02 CA CA3182080A patent/CA3182080A1/en active Pending
- 2013-05-03 UY UY0001034780A patent/UY34780A/es not_active Application Discontinuation
- 2013-05-03 TW TW102115806A patent/TW201350581A/zh unknown
- 2013-05-03 AR ARP130101507A patent/AR092317A1/es unknown
-
2015
- 2015-10-13 US US14/881,960 patent/US9803217B2/en active Active
-
2017
- 2017-09-22 US US15/713,021 patent/US10550404B2/en active Active
-
2018
- 2018-02-07 JP JP2018020063A patent/JP6629364B2/ja active Active
-
2019
- 2019-12-03 JP JP2019218839A patent/JP7100232B2/ja active Active
- 2019-12-23 US US16/725,081 patent/US20210047656A1/en not_active Abandoned
-
2022
- 2022-03-01 JP JP2022030531A patent/JP2022088372A/ja active Pending
-
2023
- 2023-01-26 US US18/160,241 patent/US20230323398A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2013164793A2 (en) | 2013-11-07 |
US20140017201A1 (en) | 2014-01-16 |
US20160097061A1 (en) | 2016-04-07 |
US20230323398A1 (en) | 2023-10-12 |
CA2872447A1 (en) | 2013-11-07 |
JP7100232B2 (ja) | 2022-07-13 |
JP2020054358A (ja) | 2020-04-09 |
US10550404B2 (en) | 2020-02-04 |
TW201350581A (zh) | 2013-12-16 |
US20210047656A1 (en) | 2021-02-18 |
EP3326655A1 (en) | 2018-05-30 |
JP2022088372A (ja) | 2022-06-14 |
CA2872447C (en) | 2023-02-21 |
US20180080046A1 (en) | 2018-03-22 |
EP2844302B1 (en) | 2023-03-15 |
CN108753824B (zh) | 2023-04-11 |
JP6290185B2 (ja) | 2018-03-07 |
CA3182080A1 (en) | 2013-11-07 |
ES2947159T3 (es) | 2023-08-02 |
CN108753824A (zh) | 2018-11-06 |
CN104470545A (zh) | 2015-03-25 |
WO2013164793A3 (en) | 2014-01-16 |
UY34780A (es) | 2013-11-29 |
JP2018108083A (ja) | 2018-07-12 |
US9163259B2 (en) | 2015-10-20 |
CN104470545B (zh) | 2018-07-06 |
JP2015517301A (ja) | 2015-06-22 |
JP6629364B2 (ja) | 2020-01-15 |
US9803217B2 (en) | 2017-10-31 |
EP2844302A2 (en) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092317A1 (es) | Vectores virales para el tratamiento de distrofia retiniana | |
MX2017004890A (es) | Metodos y composiciones para la generación o el mantenimiento de células pluripotentes. | |
MX2021005226A (es) | Regulacion de expresion genica mediada por nucleasa. | |
WO2017044857A3 (en) | Methods and compositions for the treatment of glaucoma | |
SV2015005107A (es) | Composiciones y métodos para activar la señalización que depende del estimulador del gen de interferon | |
BR112016029178A2 (pt) | composições e métodos para a expressão de rnas guia de crispr usando o promotor h1 | |
MX2019010735A (es) | Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo. | |
AR100560A1 (es) | Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido | |
WO2015073683A3 (en) | Nuclease-mediated regulation of gene expression | |
MX2018010529A (es) | Composiciones y metodos para la produccion y administracion de acido ribonucleico. | |
MX2017014346A (es) | Mejora del efecto de celulas t diseñadas por car por medio de vacunacion con acido nucleico. | |
AR091004A1 (es) | Arn en horquilla corta bifuncional (bi-arnhc) especifico de mutaciones de nucleotidos individuales en k-ras | |
PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
BR112014027813A2 (pt) | métodos e composições para integração de transgenes direcionada mediada por nuclease | |
MX2014003979A (es) | Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos. | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
MX2019007057A (es) | Composiciones de adenovirus. | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
CY1120084T1 (el) | Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων | |
TW201613949A (en) | Targeting microRNAs for metabolic disorders | |
PE20170147A1 (es) | Composiciones de oligonucleotidos y metodos para realizarlas | |
EP3238746A4 (en) | High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein | |
BR112018006026A2 (pt) | liberação de gene aperfeiçoada para células assassinas naturais, células troncos hematopoiéticas e macrófagos | |
EP3377622A4 (en) | TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES | |
PH12015500253B1 (en) | Improving pollination success and seed set in corn hybrid seed production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |